News
ALNY
224.90
+0.13%
0.30
Weekly Report: what happened at ALNY last week (0810-0814)?
Weekly Report · 1d ago
Alnylam price target lowered to $256 from $316 at Wells Fargo
TipRanks · 2d ago
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
The Motley Fool · 2d ago
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Barchart · 3d ago
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 3d ago
Alnylam Pharmaceuticals Price Target Cut to $256.00/Share From $316.00 by Wells Fargo
Dow Jones · 3d ago
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256
Benzinga · 3d ago
Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo
TipRanks · 4d ago
Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test
Simply Wall St · 4d ago
Alnylam Pharma (ALNY) Receives a Buy from Stifel Nicolaus
TipRanks · 4d ago
Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)?
Simply Wall St · 6d ago
American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review
Seeking Alpha · 08/11 13:30
Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks
TipRanks · 08/11 09:55
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Benzinga · 08/10 14:00
Weekly Report: what happened at ALNY last week (0803-0807)?
Weekly Report · 08/10 10:03
Alnylam Pharmaceuticals (ALNY) On Lowered TTR Guidance And What It Means For Valuation
Simply Wall St · 08/06 13:40
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)
TipRanks · 08/05 13:00
AI-driven tech melt-up fuels $3.5T Nasdaq 100 surge in four days
Seeking Alpha · 08/05 10:54
Alnylam Pharmaceuticals Price Target Cut to $315.00/Share From $410.00 by Truist Securities
Dow Jones · 08/04 15:39
Alnylam Pharmaceuticals Is Maintained at Buy by Truist Securities
Dow Jones · 08/04 15:39
More
Webull provides a variety of real-time ALNY stock news. You can receive the latest news about Alnylam Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.